Generex Biotechnology Corporation
GNBT · OTC
4/30/2021 | 1/31/2021 | 10/31/2020 | 7/31/2020 | |
|---|---|---|---|---|
| Revenue | $21 | $0 | $88 | $584 |
| % Growth | – | -100% | -84.8% | – |
| Cost of Goods Sold | $66 | $105 | $23 | $164 |
| Gross Profit | -$45 | -$105 | $65 | $419 |
| % Margin | -218.9% | – | 73.6% | 71.9% |
| R&D Expenses | $1,203 | $1,558 | $1,170 | $836 |
| G&A Expenses | $5,115 | $6,913 | $13,008 | $4,839 |
| SG&A Expenses | $5,115 | $6,913 | $13,008 | $4,839 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$185 |
| Operating Expenses | $6,318 | $8,472 | $14,178 | $5,491 |
| Operating Income | -$6,363 | -$8,577 | -$14,113 | -$5,256 |
| % Margin | -30,746.6% | – | -15,958.6% | -900.6% |
| Other Income/Exp. Net | $31,486 | -$15,830 | $3,124 | -$6,623 |
| Pre-Tax Income | $25,123 | -$326 | -$258 | -$11,879 |
| Tax Expense | $15,900 | -$15,243 | $4,143 | -$4,972 |
| Net Income | $9,223 | -$326 | -$258 | -$12,570 |
| % Margin | 44,566.3% | – | -291.7% | -2,153.8% |
| EPS | 0.081 | -0.22 | -0.11 | -0.15 |
| % Growth | 136.6% | -100% | 26.7% | – |
| EPS Diluted | 0.066 | -0.22 | -0.11 | -0.15 |
| Weighted Avg Shares Out | 114,605 | 110,123 | 96,859 | 76,977 |
| Weighted Avg Shares Out Dil | 140,407 | 110,123 | 96,859 | 76,977 |
| Supplemental Information | – | – | – | – |
| Interest Income | $371 | $0 | $0 | -$1 |
| Interest Expense | $1,052 | $587 | $1,019 | $1,650 |
| Depreciation & Amortization | $280 | $282 | $278 | $323 |
| EBITDA | $9,817 | -$23,537 | -$9,692 | -$9,905 |
| % Margin | 47,438.5% | – | -10,959.1% | -1,697.2% |